XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
May 10, 2021
Oct. 10, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2020
Dec. 20, 2018
Dec. 20, 2018
Revenue     $ 13,071,800 $ 11,619,076 $ 56,239,667 $ 55,406,337      
Foreign curreny translation     13,106   423,245        
Accrued interest     1,033,866   1,019,889 742,374 $ 742,374    
Net income (loss)     203,347 (2,173,903) $ (7,961,649) $ 820,786 $ 820,786    
Shares issued         17,544,509 13,485,128 13,485,128    
DOC Pharma S.A. [Member]                  
Prepaid balance     4,368,794   $ 3,263,241 $ 3,468,653 $ 3,468,653    
Accounts payable balance     220,518   565,756        
Net prepaid balance     4,148,276            
Accounts receivable balance     2,844,572   2,901,300 3,468,564 3,468,564    
Payments to purchase products     687,382 589,261 3,084,805 5,983,809      
Revenue     $ 383,688 $ 290,598 $ 978,321 2,843,260      
Description of research and development     Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($289,860) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025.   Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($295,739) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025.        
Foreign curreny translation         $ 37,411 122,279      
Pieces per product         1,000 pieces        
Inventroy purchase         $ 2,010,517        
DOC Pharma S.A. [Member] | Outsourcing Agreement [Member]                  
Pieces per product   1,000              
Inventroy purchase     $ 517,566            
Agreement term   5 years              
Grigorios Siokas [Member]                  
Interest rate               4.70% 4.70%
Accrued interest     201,835   200,683 193,585 193,585    
Outstanding principal balance     443,720   452,720 489,200 489,200    
Borrowing               $ 1,718,400 $ 1,718,400
Maturity date               Mar. 18, 2019  
Litigation settlement $ 600,000                
Plantiff attorney fees 120,000                
Litigation cost $ 4,137                
Dimitrios Goulielmos [Member]                  
Outstanding principal balance     11,315   11,544 12,475 12,475    
Gain incured     9,229            
Grigorios Siokas Three [Member]                  
Foreign curreny translation         20,623 27,114      
Outstanding principal balance         1,293,472 $ 1,629,246 $ 1,629,246    
Borrowing         2,040,635        
Additional proceeds from debt     356,085   275,306        
Repayment of loans     22,186   $ 133,552        
Net income (loss)     23,490            
Debt instrument conversion price         $ 6.00        
Convertible share description         Mr. Siokas whereby the Company exchanged an aggregate total of $6,000,000 of debt into 1,000,000 shares of Common Stock at above market prices.        
Debt instrument converted amount         $ 2,250,000        
Shares issued         375,000        
Grigorios Siokas Four [Member]                  
Additional proceeds from debt     $ 100,000